EQ vs. HCWB, IMMX, KZR, MURA, EGRX, LTRN, CELU, SCYX, KRON, and MNOV
Should you be buying Equillium stock or one of its competitors? The main competitors of Equillium include HCW Biologics (HCWB), Immix Biopharma (IMMX), Kezar Life Sciences (KZR), Mural Oncology (MURA), Eagle Pharmaceuticals (EGRX), Lantern Pharma (LTRN), Celularity (CELU), SCYNEXIS (SCYX), Kronos Bio (KRON), and MediciNova (MNOV). These companies are all part of the "pharmaceutical preparations" industry.
Equillium (NASDAQ:EQ) and HCW Biologics (NASDAQ:HCWB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, community ranking, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.
Equillium received 27 more outperform votes than HCW Biologics when rated by MarketBeat users. However, 100.00% of users gave HCW Biologics an outperform vote while only 82.50% of users gave Equillium an outperform vote.
Equillium currently has a consensus price target of $3.90, suggesting a potential upside of 122.86%. Given Equillium's higher probable upside, research analysts clearly believe Equillium is more favorable than HCW Biologics.
Equillium has higher revenue and earnings than HCW Biologics. Equillium is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.
Equillium has a net margin of -36.96% compared to HCW Biologics' net margin of -879.49%. Equillium's return on equity of -51.82% beat HCW Biologics' return on equity.
27.1% of Equillium shares are owned by institutional investors. Comparatively, 3.0% of HCW Biologics shares are owned by institutional investors. 30.3% of Equillium shares are owned by insiders. Comparatively, 45.3% of HCW Biologics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Equillium has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500. Comparatively, HCW Biologics has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500.
In the previous week, HCW Biologics had 1 more articles in the media than Equillium. MarketBeat recorded 2 mentions for HCW Biologics and 1 mentions for Equillium. HCW Biologics' average media sentiment score of 0.80 beat Equillium's score of 0.00 indicating that HCW Biologics is being referred to more favorably in the news media.
Summary
Equillium beats HCW Biologics on 11 of the 17 factors compared between the two stocks.
Get Equillium News Delivered to You Automatically
Sign up to receive the latest news and ratings for EQ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Equillium Competitors List
Related Companies and Tools
